232.50p-10.00 (-4.12%)15 Apr 2021, 16:42
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Oncimmune Holdings PLC Fundamentals

Company NameOncimmune Holdings PLCLast Updated2021-04-15
Shares in Issue69.098 mMarket Cap£160.65 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.13EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio1.0955Debt Equity Ratio0
Asset Equity Ratio-3.9498Cash Equity Ratio-1.3526
Quick Ratio1.7911Current Ratio1.89
Price To Book Value0ROCE0

Oncimmune Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Oncimmune Holdings PLC Company Financials

Tangible Assets£1.37 m£422,000.00£201,000.00
Intangible Assets£2.72 m£3.01 m£671,000.00
Total Fixed Assets£4.09 m£3.43 m£872,000.00
Debtors£1.79 m£325,000.00£291,000.00
Cash & Equivalents£4.24 m£5.36 m£12.95 m
Other Assets000
Total Assets£10.31 m£9.43 m£14.41 m
Creditors within 1 year£3.47 m£1.06 m£849,000.00
Creditors after 1 year£7.04 m£506,000.000
Other Liabilities000
Total Liabilities£10.51 m£1.57 m£849,000.00
Net assets-£194,000.00£7.87 m£13.56 m
Called up share capital£635,000.00£633,000.00£616,000.00
Share Premium£31.46 m£31.38 m£30.95 m
Profit / Loss-£9.78 m-£8.55 m-£6.34 m
Other Equity-£194,000.00£7.87 m£13.56 m
Preference & Minorities000
Total Capital Employed-£194,000.00£7.87 m£13.56 m
Debt Ratio000
Assets / Equity-3.9498-3.9498-3.9498
Cash / Equity-1.3526-1.3526-1.3526
Cash Flow202020192018
Cash from operating activities-£8.90 m-£7.36 m-£6.10 m
Cashflow before financing-£1.44 m-£7.43 m£8.18 m
Increase in Cash-£1.12 m-£7.59 m£7.88 m
Cost of sales£537,000.00£1.03 m£917,000.00
Gross Profit-£28,000.00-£859,000.00-£677,000.00
Operating Profit-£9.27 m-£8.59 m-£6.37 m
Pre-Tax profit-£9.78 m-£8.55 m-£6.34 m

Oncimmune Holdings PLC Company Background

ActivitiesOncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes EarlyCDT and ImmunoINSIGHTS. It generates maximum revenue from the EarlyCDT segment.
Latest Interim Date15 Feb 2021
Latest Fiscal Year End Date30 Oct 2020

Oncimmune Holdings PLC Directors

2016-11-07Mr. Andrew Vaughan UnittNon-Executive Director
2020-05-04Mr. Richard Simon SharpNon-Executive Director
2020-09-11Mr. Meinhard Folkert SchmidtNon-Executive Director,Chairman
2020-06-04Mr. Geoffrey Neil Hamilton-FairleyNon-Executive Director,Vice Chairman
2016-06-06Mr. Robert Hoyles PageExecutive Director,Chief Financial Officer
2020-06-05Mr. Timothy Brian BuntingNon-Executive Director,Deputy Chairman
2019-11-05Mr. Andrew MilletExecutive Director,Chief Financial Officer and Company Secretary
2020-06-04Mr. Carsten SchroederNon-Executive Director
2020-12-18Dr. Adam Mark Hill MB PhDExecutive Director,Chief Executive Officer
2021-01-19Dr. To CheungNon-Executive Director
2019-11-05Mr. Matthew HallExecutive Director,Chief Financial Officer

Oncimmune Holdings PLC Contact Details

Company NameOncimmune Holdings PLC
AddressHucknall Road, Clinical Sciences Building, City Hospital, Nottingham, NG5 1PB

Oncimmune Holdings PLC Advisors

Nominated AdviserZeus Capital Ltd
Phone+44 2038295000
AuditorGrant Thornton (UK) LLP
Phone+44 1908660666
Fax+44 1908690180
StockbrokerZeus Capital Ltd
Phone+44 2038295000
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorPeachey & Co LLP
Phone(020) 7316 5200
Fax(020) 7316 5222